- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00236145
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
January 28, 2013 updated by: Cephalon
A Randomised, Open-label, Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ (Oral Transmucosal Fentanyl Citrate) Titrated According to 2 Regimens in Patients With Cancer and Breakthrough Pain
The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a successful dose of ACTIQ treatment more quickly.
The successful ACTIQ dose provides a satisfactory combination of efficacy and tolerability after a single administration, as assessed by the patient.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria: Patients are included in the study if all of the following criteria are met:
- the patient is at least 18 years old
- women must be surgically sterile, 2 years postmenopausal, or if of child-bearing potential, must use a medically accepted method of birth control (ie, barrier method with spermicide, steroidal contraceptive [oral, implanted, and Depo-Provera contraceptives must be used in conjunction with a barrier method], or intrauterine device)
- the patient experiences persistent pain associated with cancer or cancer treatment
- for at least 7 days before enrolment, the patient has taken either the equivalent of 60 to 1000 mg/day of oral morphine around-the-clock (ATC) or 25 to 300 micrograms/hr of transdermal fentanyl to treat persistent pain
- the patient regularly experiences between 1 and 4 episodes of cancer-related BTP per day while taking ATC opioid therapy
- the patient experiences at least partial relief of cancer related BTP by administering conventional opioid BTP medication at a dose approximately in the range of one-fifth to one-sixth the 24-hour sustained release dose
- the patient is capable of self-administering ACTIQ by sucking lozenge, producing sufficient saliva to dissolve the lozenge over 15 minutes, and swallowing the saliva
- a responsible adult caregiver is available to assist the patient in case of emergency if the patient will be taking ACTIQ at home
- the patient willingly provides informed consent to participate in this study
Exclusion Criteria: Patients are excluded from participating in this study if 1 or more of the following criteria are met:
- the patient experiences uncontrolled or rapidly escalating pain, as determined by the investigator, such that ATC administration of pain medication might be expected to change between the first and last administrations of ACTIQ.
- the patient has known or suspected hypersensitivities and/or allergies to fentanyl
- the patient has a recent history or current evidence or abuse of alcohol or any other drug substance, licit or collection
- the patient has neurological or psychiatric disease sufficient, in the investigator's opinion, to compromise data collection
- the patient received strontium-89 therapy within 6o days prior to entering the study
- the patient received any other therapy (eg, radiotherapy) within a 1 week period prior to entering the study that, in the investigator's opinion, could alter pain or response to pain medication
- the patient has moderate to severe oral mucositis
- the patient is pregnant, nursing, or is of child-bearing potential or not taking adequate contraceptive measures
- the patient has previously been treated with ACTIQ
- the patient has participated in a trial of an unapproved drug in the previous 8 weeks
- the patient has been diagnosed with either severe respiratory depression or severe obstructive lung conditions
- the patient has used monoamine-oxidase inhibitors (MAOI's) within the 2-week period prior to entering the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
to determine if ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2004
Primary Completion (ACTUAL)
August 1, 2005
Study Registration Dates
First Submitted
October 7, 2005
First Submitted That Met QC Criteria
October 7, 2005
First Posted (ESTIMATE)
October 12, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
January 29, 2013
Last Update Submitted That Met QC Criteria
January 28, 2013
Last Verified
October 1, 2005
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C8278A/302/ON/MN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breakthrough Pain
-
Kyowa Kirin Co., Ltd.Completed
-
University Hospital, Basel, SwitzerlandTerminatedCancer: Breakthrough Pain | Cancer: Extreme Pain on MovementSwitzerland
-
Rajavithi HospitalCompletedEfficacy of Injectable Fentanyl in Sublingual Route Versus Oral Morphine Syrup for Breakthrough PainPain, BreakthroughThailand
-
KK Women's and Children's HospitalRecruitingLabor Pain | Breakthrough PainSingapore
-
CephalonTerminatedBreakthrough Pain | Cancer PainSpain, Germany, France, Ireland, Italy, Poland, United Kingdom
-
KK Women's and Children's HospitalCompleted
-
Seoul National UniversityWithdrawnBreakthrough Pain | Cancer Pain
-
KK Women's and Children's HospitalActive, not recruiting
-
Kyowa Kirin Co., Ltd.Completed
-
Aziende Chimiche Riunite Angelini Francesco S.p.ATerminatedBreakthrough Cancer PainPoland
Clinical Trials on ACTIQ (Oral transmucosal fentanyl citrate)
-
CephalonCompletedPain | Cancer | Sickle Cell Anemia | Severe BurnsUnited States, Canada, Puerto Rico
-
Cairo UniversityUnknownEdentulous Alveolar Ridge | Edentulous Jaw | Edentulous MouthEgypt
-
Centre Henri BecquerelUnknown
-
MallinckrodtCompleted
-
INSYS Therapeutics IncCompleted
-
Samuel Lunenfeld Research Institute, Mount Sinai...Terminated
-
Nanjing Medical UniversityCompleted
-
Kyowa Kirin Co., Ltd.Completed
-
University Hospital, MontpellierTerminated